Dipal Doshi - 28 Oct 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship: President and CEO, Director
Issuer ticker: TRDA
Reported as of: 28 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Nov 2021, 18:57:52 UTC
Next SEC filing: 18 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Jared Cohen, as Attorney-in-Fact

Filing notes and source

Key filing fact

Dipal Doshi filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 01 Nov 2021.

Key facts

This page summarizes Dipal Doshi's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Nov 2021, 18:57.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRDA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +184,821
Change %
Price: $0.000000
Shares after: 184,821
Date: 28 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 184,821
Exercise price: $20.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable in 48 equal monthly installments commencing on October 28, 2021 (the "Vesting Start Date"), such that the option shares shall be fully vested on the four-year anniversary of the Vesting Start Date.